FDA's "least burdensome" guidance disappoints industry
This article was originally published in Clinica
Executive Summary
Device companies were surprised and disappointed to learn last week that the FDA's much-anticipated guidance covering the "least burdensome" path to win product approval will be more narrow in scope than had been envisaged.